Search

everythinglearnresearchcommunity

for

Search:↓

Proactive monitoring and management are essential to maximize the benefits of Trastuzumab Deruxtecan while minimizing serious side effects.

Tofacitinib helped regrow hair in people with severe alopecia, but side effects occurred and benefits stopped after treatment ended.

Oral tofacitinib helped regrow hair in over half of the patients with severe alopecia, but relapses and side effects were common.

IMTA can help regrow hair in severe alopecia areata when JAK inhibitors don't work well.

Hydroxytyrosol helps reduce liver injury by blocking certain inflammation pathways.

Rapamycin may help treat Leigh syndrome by targeting protein kinase C.

Blocking a certain signal in the gp130 receptor can improve tissue healing and lessen osteoarthritis symptoms.

Patients with rheumatoid arthritis using tofacitinib had more serious side effects than those with alopecia areata.

Topical aprepitant reduces skin rash and hair loss caused by cancer treatment.

Baricitinib may reactivate trichilemmal cysts in people with a history of these cysts.

New oral treatments for adult hair loss show promise, especially JAK inhibitors, with mild side effects.

Access to JAK inhibitors for alopecia areata should be improved in the Military Healthcare System.

Baricitinib successfully treated severe hair loss.

Using CDK inhibitors on rats showed a reduction in chemotherapy-caused hair loss, but later experiments could not repeat these results.

Ritlecitinib effectively reduces severe hair loss in alopecia areata over 24 months.

Baricitinib is effective in promoting hair growth in severe alopecia areata.

New cancer drugs can cause skin side effects like rashes, dry skin, hair changes, and nail problems.

Switching JAK inhibitors or using dupilumab may help some alopecia areata patients who don't respond well to initial treatments.

Ruxolitinib may help treat hair loss and symptoms in patients with chronic graft-versus-host disease.

Machine learning can predict how well patients with alopecia areata will respond to certain treatments.

Upadacitinib may effectively treat resistant lichen planopilaris.

Tofacitinib is effective and safe for long-term treatment of severe alopecia areata, with many patients achieving complete hair regrowth.

Tick bites can cause hair loss similar to alopecia areata, and baricitinib may help regrow hair.

Tolvaptan can slow kidney disease progression, but doesn't affect mortality or kidney failure.

New cytokine-targeted therapies show promise for treating alopecia areata.

Baricitinib may not always prevent relapse in alopecia areata.

Activating Tgr5 may help treat hair loss and bone loss.

SGK1 is important in cancer growth and treatment resistance, and targeting it could improve therapies.

Baricitinib helps regrow hair in severe alopecia areata but has side effects like infections and headaches.